Recombinant Mouse Complement component C1q receptor (Cd93)

What is mouse Complement Component C1q Receptor (CD93) and what are its alternative names?

Mouse Complement Component C1q Receptor (CD93) is a transmembrane glycoprotein originally identified as a receptor for C1q, though this function has been contested in recent research. It is also known by several alternative names including C1q/MBL/SPA receptor, C1qR(p), C1qRp, Cell surface antigen AA4, Complement component 1 q subcomponent receptor 1, Lymphocyte antigen 68 (Ly-68), and CD antigen CD93 . Understanding the nomenclature evolution is important when reviewing historical literature, as earlier publications may refer to this protein exclusively by its former designations.

What is the molecular structure and properties of recombinant mouse CD93?

Recombinant mouse CD93 is a protein with a molecular weight of approximately 60.9 kDa . The target protein sequence spans amino acids 23-572 of the native protein (UniProtKB ID: O89103) . When produced recombinantly, it is typically expressed in mammalian cell systems to ensure proper folding and post-translational modifications. The protein contains multiple functional domains including a C-type lectin-like domain, which has been implicated in several biological functions . Recombinant preparations typically achieve greater than 95% purity as determined by SDS-PAGE analysis and contain less than 1.0 EU/μg of endotoxin when measured by the Limulus Amebocyte Lysate (LAL) method .

How is recombinant mouse CD93 typically produced for research applications?

Recombinant mouse CD93 protein is most commonly produced using mammalian cell expression systems . This approach is preferred over bacterial expression systems because it facilitates proper protein folding and post-translational modifications that are critical for maintaining the protein's biological activity. For research applications, the recombinant protein is often engineered with specific tags such as a C-terminal 10-histidine tag (C-10His) to facilitate purification and detection . The protein is typically supplied as a lyophilized powder, which helps maintain stability during shipping and storage. For functional studies, different formats may be available, including Fc chimera proteins that combine CD93 with the Fc region of human IgG1 .

What is the current understanding of CD93's biological role?

The biological role of CD93 has been the subject of considerable scientific debate. Initially characterized as a receptor for C1q that enhanced phagocytosis, more recent studies have challenged this interpretation . Research using CD93-deficient mice has revealed that these animals are viable with no gross developmental abnormalities . While CD93 was thought to be involved in C1q-dependent enhancement of phagocytosis, thioglycolate-elicited peritoneal macrophages from CD93-deficient mice showed similar enhancement in complement- and FcγR-dependent uptake of red blood cells compared to wild-type macrophages .

Significant findings suggest CD93 plays a role in the clearance of apoptotic cells in vivo, as CD93-deficient mice demonstrated a significant phagocytic defect in this process (human Jurkat T cells: p = 0.0006; murine thymocytes: p = 0.0079) . Interestingly, this defect was not observed in in vitro assays, suggesting the involvement of additional factors in the in vivo environment .

Additionally, evidence indicates that CD93 may function in intercellular adhesion processes, particularly in vascular endothelial cells where it shows predominant expression .

How do findings from CD93 knockout models inform our understanding of its function?

The most notable finding is a significant defect in the clearance of apoptotic cells in vivo. When apoptotic cells (both human Jurkat T cells and murine thymocytes) were injected into the peritoneal cavity of CD93−/− mice, there was significantly reduced phagocytic clearance compared to wild-type controls (p = 0.0006 and p = 0.0079, respectively) . This suggests that CD93 contributes to the efficient removal of dying cells in living organisms.

Interestingly, this clearance defect was not observed in in vitro experiments, where CD93−/− macrophages showed similar engulfment of apoptotic cells as wild-type macrophages . This discrepancy between in vivo and in vitro results suggests that CD93 may be involved in complex mechanisms that are only present in the intact organism, possibly involving interactions with other components of the immune system.

Contrary to earlier hypotheses, CD93−/− macrophages showed normal enhancement in complement- and FcγR-dependent phagocytosis when plated on C1q-coated surfaces, challenging the notion that CD93 functions as a C1q receptor in these processes .

What are the contradictions in the literature regarding CD93's interaction with C1q?

A significant contradiction in the scientific literature concerns whether CD93 (formerly known as C1qRp) actually functions as a receptor for the complement component C1q. Early studies suggested that human CD93 was a phagocytic receptor involved in C1q-dependent enhancement of phagocytosis, leading to its initial designation as C1qRp (C1q receptor protein) .

The proposed role of CD93 in phagocytic responses has also been questioned. In human tissues, CD93 is predominantly expressed on endothelial cells rather than macrophages, which would be expected if it were primarily involved in phagocytosis . Additionally, CD93 knockout mice show normal C1q-mediated enhancement of phagocytosis, further undermining its proposed role as a C1q receptor .

This evolving understanding has led to a conceptual shift, with researchers now suggesting that CD93 may function primarily in intercellular adhesion rather than as a complement receptor . This highlights the importance of critically evaluating historical literature and demonstrates how scientific understanding evolves as new experimental evidence emerges.

What functional assays are available for evaluating recombinant mouse CD93 activity?

Several functional assays have been developed to evaluate the biological activity of recombinant mouse CD93, reflecting the evolving understanding of this protein's functions:

Binding assays: The activity of recombinant mouse CD93 can be measured by its binding ability in functional enzyme-linked immunosorbent assays (ELISA). For example, immobilized mouse CD93 at 2 μg/mL can bind mouse insulin-like growth factor binding protein 7 (IGFBP7) with an EC50 of 373.4-836.8 ng/mL . This assay provides a quantitative measure of the protein's binding capacity.

Adhesion assays: Given the evidence supporting CD93's role in intercellular adhesion, assays that measure adhesive interactions are particularly relevant. Recombinant CD93-Fc chimeras containing the C-type lectin-like domain have been shown to bind specifically to vascular endothelial cells in sections of inflamed tissue . This interaction is calcium-independent and can be blocked by specific monoclonal antibodies (mAbs), providing a way to assess functional activity.

Phagocytosis assays: Despite uncertainties about CD93's role as a C1q receptor, phagocytosis assays remain valuable for studying its potential contributions to clearance of apoptotic cells. In vivo assays involving injection of labeled apoptotic cells into wild-type and CD93-deficient mice have revealed significant differences in clearance efficiency .

Antibody-based blocking studies: Monoclonal antibodies against different epitopes of CD93 can be used to block specific interactions and evaluate their functional significance. For example, the mAb mNI-11 has been shown to block the binding of a recombinant C1qRp-Fc chimera to vascular endothelial cells .

How can researchers design experiments to distinguish between CD93's role in apoptotic cell clearance versus other phagocytic processes?

Designing experiments to distinguish between CD93's role in apoptotic cell clearance versus other phagocytic processes requires thoughtful experimental approaches that isolate specific mechanisms. Based on current research, several methodological strategies are recommended:

Comparative in vivo versus in vitro studies: The observed discrepancy between CD93's role in apoptotic cell clearance in vivo (deficient in CD93−/− mice) versus in vitro (normal clearance by CD93−/− macrophages) provides a valuable experimental framework . Researchers should design parallel in vivo and in vitro experiments using identical cell types and conditions, systematically introducing factors present in the in vivo environment (e.g., serum components, extracellular matrix proteins) to the in vitro system to identify the critical elements that make CD93 necessary in vivo.

Specificity of phagocytic targets: Experiments should compare the phagocytosis of different targets by CD93-sufficient and CD93-deficient cells. These targets should include:

• Apoptotic cells (e.g., UV-irradiated thymocytes)

• Antibody-opsonized particles (to test FcγR-dependent phagocytosis)

• Complement-opsonized particles (to test complement-dependent phagocytosis)

• Non-opsonized microorganisms

Domain-specific analysis: Recombinant CD93 constructs containing different functional domains (e.g., C-type lectin domain only, transmembrane domain deleted) can help identify which regions are essential for specific functions . These constructs can be used in rescue experiments with CD93-deficient cells or in competition assays with full-length CD93.

Temporal analysis of CD93 involvement: Time-course experiments tracking CD93 localization during phagocytosis using fluorescently tagged CD93 can determine at which stage of phagocytosis (recognition, engulfment, processing) CD93 is most active.

Tissue-specific knockout models: Since CD93 is predominantly expressed on endothelial cells rather than macrophages in human tissues , cell-type specific knockout models would help clarify whether CD93's role in apoptotic cell clearance is direct (expressed on the phagocyte) or indirect (expressed on neighboring cells).

What are the key considerations when designing experiments using recombinant mouse CD93?

When designing experiments with recombinant mouse CD93, researchers should consider several critical factors to ensure reliable and interpretable results:

Protein formulation and reconstitution: Recombinant mouse CD93 is typically supplied as a lyophilized powder , which requires proper reconstitution before use. Researchers should follow manufacturer-specific protocols for reconstitution, typically using sterile buffer solutions. The reconstituted protein should be handled carefully to avoid denaturation through excessive agitation or temperature fluctuations.

Expression system compatibility: The recombinant protein's expression system affects its structural and functional properties. Mouse CD93 produced in mammalian cell systems maintains post-translational modifications that may be critical for certain interactions. Researchers should ensure the expression system used is appropriate for their specific experimental questions.

Tag interference: Recombinant CD93 proteins often contain tags such as His-tags or Fc fusion partners that facilitate purification and detection. These tags may potentially interfere with certain protein interactions or functions. Control experiments using alternatively tagged versions or tag-cleaved proteins should be considered for key findings.

Endotoxin considerations: Even low levels of endotoxin contamination can significantly affect immune cell experiments. High-quality recombinant CD93 preparations should have endotoxin levels below 1.0 EU/μg . For particularly sensitive experiments, additional endotoxin removal may be necessary.

Experimental controls: Appropriate controls are essential, including:

• Isotype-matched control proteins for Fc chimeras

• Heat-inactivated CD93 to control for non-specific effects

• Blocking antibodies to confirm specificity of observed effects

• Comparison with native (non-recombinant) CD93 where possible

Concentration optimization: Activity of recombinant CD93 is concentration-dependent, with effective concentrations ranging from 2 μg/mL (for binding assays) to 6-30 μg/mL for other functional effects . Dose-response experiments should be conducted to determine optimal concentrations for specific experimental systems.

How should researchers interpret contradictory results between in vitro and in vivo studies of CD93 function?

The contradictory results between in vitro and in vivo studies of CD93 function, particularly regarding its role in phagocytosis, present a complex interpretive challenge for researchers. When faced with such discrepancies, consider the following analytical approach:

Recognize the complexity of the in vivo environment: The in vivo system contains numerous factors absent from simplified in vitro models. These include diverse cell populations, extracellular matrix components, soluble mediators, and complex three-dimensional architecture. The observation that CD93−/− mice show defects in apoptotic cell clearance in vivo but not in isolated macrophage assays in vitro suggests that CD93 may function within a network of interactions that are not fully recapitulated in culture systems .

Consider indirect mechanisms: CD93 is predominantly expressed on endothelial cells rather than macrophages in human tissues . This expression pattern suggests that CD93 may influence phagocytosis indirectly—perhaps by mediating interactions between phagocytes and the vascular endothelium, facilitating the recruitment of phagocytes to sites of apoptotic cell accumulation, or modulating the local inflammatory environment.

Examine temporal dynamics: In vivo systems involve dynamic processes occurring over extended periods, while in vitro assays typically measure events within a restricted timeframe. CD93's role may be more prominent during specific phases of the immune response that are not adequately captured in short-term in vitro assays.

Analyze compensatory mechanisms: In vitro systems may allow for compensatory mechanisms that mask CD93's role. For example, in the absence of certain serum components or cell-cell interactions, alternative phagocytic receptors might compensate for CD93 deficiency in isolated macrophages, while such compensation may be insufficient in the more complex in vivo environment.

Systematically bridge the gap: To resolve contradictions, researchers should design experiments that systematically introduce in vivo complexity to in vitro systems. This could involve using co-culture systems, three-dimensional matrices, inclusion of serum components, or ex vivo tissue explants. Conversely, more sophisticated in vivo imaging techniques might provide insights into CD93's function with cellular resolution in the intact organism.

What methodological approaches are recommended for studying CD93's potential role in intercellular adhesion?

Based on emerging evidence suggesting CD93 functions in intercellular adhesion rather than as a complement receptor , the following methodological approaches are recommended for investigating this aspect of CD93 biology:

Static adhesion assays: Researchers can coat plates with recombinant CD93 or CD93-Fc chimeras and quantify the adhesion of various cell types, particularly those expressing potential CD93 ligands. This approach can help identify cell populations that interact with CD93 and establish baseline adhesive properties.

Flow-based adhesion assays: Since CD93 is predominantly expressed on endothelial cells , flow chamber systems that mimic vascular conditions provide a physiologically relevant context for studying CD93-mediated adhesion. These systems can measure rolling, firm adhesion, and transmigration of leukocytes across CD93-expressing endothelial monolayers under controlled shear stress conditions.

Domain-specific functional analysis: Recombinant CD93 constructs containing specific domains (particularly the C-type lectin-like domain) should be used to pinpoint which regions mediate adhesive interactions. The observation that a recombinant C1qRp-Fc chimera containing just the C-type lectin-like domain binds to vascular endothelial cells provides a starting point for these analyses.

Antibody blocking studies: The monoclonal antibody mNI-11 has been shown to block CD93-mediated adhesive interactions . A panel of domain-specific antibodies can help map the functional epitopes involved in CD93's adhesive properties. Additionally, the finding that mNI-11 (Fab') promotes monocyte-monocyte and monocyte-endothelial cell adhesive interactions suggests complex regulatory mechanisms that warrant detailed investigation.

Calcium dependence analysis: The observation that CD93's interaction with vascular endothelial cells is calcium-independent distinguishes it from many C-type lectin interactions. Systematic analysis of divalent cation requirements for CD93-mediated adhesion in different contexts may reveal distinct binding mechanisms or multiple ligands.

Identification of binding partners: Techniques such as crosslinking followed by mass spectrometry, proximity labeling, or protein microarrays can help identify CD93's molecular interaction partners on different cell types. Confirming these interactions through co-immunoprecipitation and direct binding assays is essential for understanding the molecular basis of CD93-mediated adhesion.

What are the common challenges in producing and working with recombinant mouse CD93, and how can they be addressed?

Researchers working with recombinant mouse CD93 face several technical challenges that can impact experimental outcomes. Here are the most common issues and recommended solutions:

Protein solubility and aggregation: CD93 is a transmembrane protein with multiple domains, making it prone to aggregation when expressed recombinantly.

• Solution: Use mammalian expression systems that provide appropriate post-translational modifications . Incorporate solubility-enhancing tags or fusion partners. Store reconstituted protein in small aliquots to avoid freeze-thaw cycles. Consider adding low concentrations (0.1-0.5%) of non-ionic detergents for storage if aggregation is problematic.

Functionality verification: Ensuring that recombinant CD93 retains native functionality can be challenging, especially given the evolving understanding of its biological roles.

• Solution: Employ multiple functional assays including binding assays (e.g., ELISA with known interaction partners like mouse IGFBP7) , cell adhesion assays, and antibody recognition tests using well-characterized monoclonal antibodies. Compare results with native CD93 wherever possible.

Tag interference: His-tags or Fc fusion partners used in recombinant CD93 may alter protein behavior or block interaction sites.

• Solution: Compare results obtained with differently tagged versions of the protein. For critical experiments, consider using tag-free protein or including tag-only controls. Position tags away from known functional domains when designing constructs.

Endotoxin contamination: Recombinant proteins produced in bacterial systems may contain endotoxins that activate immune cells, confounding experimental results.

• Solution: Use endotoxin-tested preparations (<1.0 EU/μg) or perform additional endotoxin removal if necessary. Include endotoxin inhibitors (e.g., polymyxin B) in sensitive assays as appropriate.

Storage stability: Lyophilized proteins may lose activity over time or after reconstitution.

• Solution: Store lyophilized protein at -20°C to -80°C. After reconstitution, store working aliquots at -80°C and avoid repeated freeze-thaw cycles. Add carrier proteins (e.g., BSA) to dilute solutions to prevent adsorption to tube walls. Verify activity periodically using standardized functional assays.

How can researchers effectively design knockout or knockdown studies to investigate CD93 function?

Effective design of knockout or knockdown studies to investigate CD93 function requires careful consideration of several methodological aspects:

Selection of knockout/knockdown strategy:

• Complete knockout: Generation of CD93−/− mice through embryonic stem cell targeting or CRISPR/Cas9 approaches provides a comprehensive model for studying CD93 deficiency . This approach is most suitable for investigating systemic effects and in vivo phenotypes.

• Conditional knockout: Given CD93's expression in multiple cell types, conditional knockout systems (e.g., Cre-loxP) allow cell-type specific deletion, enabling investigation of CD93's role in specific cellular contexts (e.g., endothelial cells versus myeloid cells).

• Inducible knockout: Temporal control of CD93 deletion using inducible systems (e.g., tamoxifen-inducible Cre) can help distinguish between developmental and functional roles.

• RNA interference: siRNA or shRNA approaches provide temporary knockdown that may be useful for acute studies or in systems where genetic manipulation is challenging.

Verification of knockout/knockdown efficiency:

• Multiple methods should be used to confirm CD93 deletion, including:

  • PCR genotyping for genomic alterations

  • RT-PCR for mRNA expression

  • Western blotting for protein expression

  • Flow cytometry for cell surface expression

• Complete absence of compensatory upregulation of related proteins should be verified

Experimental controls:

• Wild-type controls: Littermate controls should be used whenever possible to minimize genetic background effects.

• Heterozygous animals: Include CD93+/− animals to assess gene dosage effects.

• Rescue experiments: Reintroduction of CD93 through transgenic expression or recombinant protein administration confirms that phenotypes are directly attributable to CD93 deficiency.

• Domain-specific mutants: If complete knockout shows a phenotype, follow-up with expression of mutants lacking specific domains to map functional regions.

Phenotypic analysis:

• Comprehensive phenotyping should include:

  • Baseline characterization (development, viability, basic immune parameters)

  • Functional assays targeting suspected roles (e.g., apoptotic cell clearance)

  • Challenge models to reveal phenotypes not apparent under homeostatic conditions

  • Age-related changes, as some phenotypes may develop over time

  • Tissue-specific analyses, focusing on sites of high CD93 expression

Mechanistic follow-up:

• When phenotypes are identified, molecular mechanisms should be investigated through:

  • Transcriptomic analysis to identify altered gene expression patterns

  • Phosphoproteomic analysis to identify altered signaling pathways

  • Interaction studies to identify disrupted protein-protein interactions

  • Detailed cellular assays to pinpoint specific affected processes

What approaches can help resolve the discrepancies between CD93's originally proposed function as a C1q receptor and newer findings?

Resolving the discrepancies between CD93's originally proposed function as a C1q receptor and newer findings challenging this role requires systematic experimental approaches:

Direct binding studies with improved methodology:

• Surface plasmon resonance (SPR): Perform quantitative binding studies between purified CD93 and C1q using SPR to obtain kinetic and affinity data. Previous studies showing that soluble recombinant C1qRp-Fc chimera failed to interact with immobilized C1q should be extended using multiple protein orientations and conditions.

• Proximity labeling techniques: In situ proximity labeling (BioID, APEX) in living cells expressing CD93 can identify proteins that physically associate with CD93 under physiological conditions, directly testing whether C1q is a binding partner.

• Structural studies: Cryo-electron microscopy or X-ray crystallography of CD93 alone and in complex with potential binding partners can reveal structural features that support or refute direct interactions.

Functional studies with molecularly defined components:

• Reconstitution experiments: Using cells lacking both CD93 and C1q, systematically reintroduce wild-type or mutant versions of each protein to determine if and how they functionally interact.

• Domain-specific mutations: Generate CD93 variants with targeted mutations in domains originally implicated in C1q binding and assess their ability to restore function in CD93-deficient systems.

• Competitive inhibition: If CD93 truly functions as a C1q receptor, soluble CD93 should competitively inhibit C1q-dependent processes. This prediction can be directly tested in various functional assays.

Reconciliation of species differences:

• Comparative analysis: Systematic comparison of human, mouse, and other species' CD93 regarding sequence, structure, expression patterns, and functional properties may reveal species-specific differences that explain contradictory findings.

• Cross-species complementation: Determining whether human CD93 can functionally replace mouse CD93 (and vice versa) in various assays can clarify whether the proteins have diverged functionally between species.

Context-dependent function assessment:

• Microenvironmental factors: Investigate whether CD93's ability to interact with C1q depends on specific microenvironmental factors (pH, calcium concentration, presence of specific co-factors) that might be present in some experimental systems but not others.

• Cell type specificity: Systematically compare CD93's functions in different cell types, particularly comparing endothelial cells (where CD93 is predominantly expressed in humans ) versus macrophages (where it was originally characterized as a phagocytic receptor).

Integration of new functional paradigms:

• Bridging adhesion and complement biology: Explore models in which CD93's primary role in adhesion indirectly influences complement-dependent processes, potentially explaining why it was initially identified in screens for complement receptors.

• Temporal dynamics: Investigate whether CD93 interacts transiently with C1q during specific cellular processes, explaining why stable interactions are not detected in equilibrium binding assays.

What are the most promising avenues for future research on CD93's biological functions?

Based on current understanding and unresolved questions, several promising research directions emerge for advancing our knowledge of CD93's biological functions:

Molecular mechanisms of apoptotic cell clearance: The significant defect in apoptotic cell clearance observed in CD93−/− mice in vivo, despite normal clearance by isolated macrophages in vitro , represents a critical knowledge gap. Future research should:

• Identify the specific step in the clearance process affected by CD93 deficiency

• Determine whether CD93 directly recognizes apoptotic cells or facilitates interactions with other recognition receptors

• Investigate how CD93 cooperates with other clearance mechanisms in the complex in vivo environment

Endothelial CD93 functions: Given the predominant expression of CD93 on endothelial cells in human tissues , focused investigation of its role in vascular biology is warranted. Key areas include:

• Effects on endothelial barrier function and permeability

• Role in leukocyte trafficking across the endothelium

• Potential contributions to angiogenesis and vascular remodeling

• Involvement in endothelial responses to inflammatory stimuli

Identification of physiological ligands: The C-type lectin-like domain of CD93 has been shown to bind to vascular endothelial cells , but the molecular identity of its ligand(s) remains unknown. Unbiased approaches to ligand identification would significantly advance the field:

• Proximity labeling of CD93 interaction partners in relevant physiological contexts

• Glycan array screening to identify potential carbohydrate ligands

• Proteomic analysis of proteins co-precipitating with CD93 under various conditions

Role in disease processes: Extending research beyond basic biology into disease relevance is an important future direction. Potential areas include:

• CD93's role in atherosclerosis and vascular inflammation

• Contributions to tumor angiogenesis and metastasis

• Involvement in autoimmune diseases, particularly those with vascular components

• Potential as a therapeutic target in inflammatory conditions

Signaling mechanisms: Understanding the intracellular signaling pathways activated downstream of CD93 would provide insights into its cellular functions:

• Identification of cytoplasmic binding partners of CD93's intracellular domain

• Characterization of post-translational modifications regulating CD93 signaling

• Analysis of transcriptional changes induced by CD93 activation or deficiency

How might CD93 research impact our understanding of the complement system and phagocytosis?

Despite challenges to CD93's originally proposed role as a C1q receptor, ongoing research into this protein continues to offer valuable insights that may reshape our understanding of complement biology and phagocytic processes:

Refinement of complement receptor paradigms: The evolving understanding of CD93 exemplifies how initial characterizations of complement receptors may need refinement as molecular techniques advance. This case study encourages critical reevaluation of other proposed complement receptors, particularly those identified through functional screens rather than direct binding assays.

Bridge between complement and cellular adhesion: Although CD93 may not directly bind C1q , its predominant expression on endothelial cells and potential role in adhesion suggest it may function at the interface between complement activation and cellular responses. This represents a conceptual shift from viewing complement receptors as simple recognition molecules toward understanding them as integrators of multiple immune processes.

Contextual regulation of phagocytosis: The discrepancy between CD93's effects on apoptotic cell clearance in vivo versus in vitro highlights the importance of contextual factors in regulating phagocytosis. This finding encourages a broader experimental approach that considers how the tissue microenvironment modulates phagocytic receptor function—a perspective that may apply to other phagocytic receptors as well.

Tissue-specific complement functions: The expression pattern of CD93 on endothelial cells rather than macrophages in human tissues suggests tissue-specific roles for complement-associated molecules that extend beyond classical complement functions. This may lead to new appreciation for how complement components and their receptors function in particular tissue niches.

Integration of apoptotic clearance mechanisms: The defect in apoptotic cell clearance in CD93−/− mice contributes to our understanding of the redundant yet interdependent mechanisms that ensure efficient removal of dying cells. Future research may reveal how CD93 cooperates with established apoptotic cell receptors and whether this cooperation involves complement components like C1q, which are known to bind apoptotic cells.

Evolutionary perspectives: Comparative studies of CD93 across species may provide evolutionary insights into how molecules at the interface of innate immunity and tissue homeostasis have adapted to species-specific immune challenges while maintaining core functions in processes like apoptotic cell clearance.

What technological advances could accelerate progress in understanding CD93 biology?

Several cutting-edge technological approaches could significantly accelerate our understanding of CD93 biology by overcoming current methodological limitations:

Advanced imaging technologies:

• Super-resolution microscopy: Techniques such as STORM, PALM, or STED microscopy can visualize CD93's nanoscale organization on the cell surface and its dynamic interactions with other molecules during processes like phagocytosis or cell adhesion.

• Intravital imaging: Real-time visualization of fluorescently tagged CD93 in living organisms would provide unprecedented insights into its dynamics during immune responses, particularly during apoptotic cell clearance where CD93−/− mice show defects in vivo .

• Correlative light and electron microscopy (CLEM): This approach could reveal both the molecular interactions and ultrastructural context of CD93 during cellular processes.

Structural biology approaches:

• Cryo-electron microscopy: Determining the structure of full-length CD93 and its complexes with potential binding partners would provide critical insights into its functional mechanisms.

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS): This technique could map conformational changes in CD93 upon interaction with various potential ligands or during activation states.

• Single-molecule force spectroscopy: Measuring the mechanical properties of CD93-mediated adhesive interactions would provide insights into its role in processes requiring cell-cell or cell-matrix adhesion.

Genetic and genomic technologies:

• CRISPR-based screening: Genome-wide CRISPR screens in CD93-expressing cells could identify genes that functionally interact with CD93 in processes like apoptotic cell clearance.

• Single-cell transcriptomics: Analyzing gene expression changes in individual cells from CD93-deficient versus wild-type tissues would reveal cell type-specific responses to CD93 deficiency.

• Spatial transcriptomics: This approach could map how CD93 deficiency affects gene expression patterns across tissue microenvironments, potentially explaining the in vivo versus in vitro discrepancies observed in phagocytosis assays .

Protein interaction technologies:

• Proximity labeling in living systems: Techniques such as TurboID or APEX2 fused to CD93 would enable identification of its interaction partners in physiologically relevant contexts.

• Optical control of protein function: Photoswitchable versions of CD93 would allow precise temporal control over its activity, helping to dissect its acute versus chronic functions.

• Synthetic receptor biology: Engineering chimeric receptors containing CD93 domains fused to heterologous signaling domains could help map structure-function relationships and signaling pathways.

Organoid and microphysiological systems:

• Vascular organoids: Given CD93's expression on endothelial cells , vascular organoids would provide a physiologically relevant system for studying its functions in a complex 3D environment.

• Immune-vascular co-culture systems: Microfluidic devices that incorporate both immune cells and vascular structures could bridge the gap between simplistic in vitro cultures and complex in vivo systems, potentially resolving contradictions between these experimental approaches.